164 related articles for article (PubMed ID: 27510179)
1. Selective expansion of regulatory T cells during lenalidomide treatment of myelodysplastic syndrome with isolated deletion 5q.
Balaian E; Schuster C; Schönefeldt C; Germing U; Haase D; Tuve S; Ordemann R; Ehninger G; Bornhäuser M; Oelschlaegel U; Mohr B; von Bonin M; Platzbecker U; Wermke M
Ann Hematol; 2016 Oct; 95(11):1805-10. PubMed ID: 27510179
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide treatment induced the normalization of marker protein levels in blood plasma of patients with 5q-myelodysplastic syndrome.
Messingerová L; Jonášová A; Barančik M; Poleková L; Šereš M; Gibalová L; Breier A; Sulová Z
Gen Physiol Biophys; 2015 Oct; 34(4):399-406. PubMed ID: 26001289
[TBL] [Abstract][Full Text] [Related]
3. Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide.
Merkerova MD; Krejcik Z; Belickova M; Hrustincova A; Klema J; Stara E; Zemanova Z; Michalova K; Cermak J; Jonasova A
Eur J Haematol; 2015 Jul; 95(1):35-43. PubMed ID: 25287904
[TBL] [Abstract][Full Text] [Related]
4. High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide.
Jonasova A; Bokorova R; Polak J; Vostry M; Kostecka A; Hajkova H; Neuwirtova R; Siskova M; Sponerova D; Cermak J; Mikulenkova D; Cervinek L; Brezinova J; Michalova K; Fuchs O
Eur J Haematol; 2015 Jul; 95(1):27-34. PubMed ID: 25284710
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Talati C; Sallman D; List A
Semin Hematol; 2017 Jul; 54(3):159-166. PubMed ID: 28958290
[TBL] [Abstract][Full Text] [Related]
6. Treatment of Patients With Myelodysplastic Syndrome With Lenalidomide in Clinical Routine in Austria.
Aschauer G; Greil R; Linkesch W; Nösslinger T; Stauder R; Burgstaller S; Fiegl M; Fridrik M; Girschikofsky M; Keil F; Petzer A
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e143-9. PubMed ID: 26422252
[TBL] [Abstract][Full Text] [Related]
7. Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes.
Giagounidis A; Mufti GJ; Fenaux P; Germing U; List A; MacBeth KJ
Ann Hematol; 2014 Jan; 93(1):1-11. PubMed ID: 24018623
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis.
Lian XY; Zhang ZH; Deng ZQ; He PF; Yao DM; Xu ZJ; Wen XM; Yang L; Lin J; Qian J
PLoS One; 2016; 11(11):e0165948. PubMed ID: 27824902
[TBL] [Abstract][Full Text] [Related]
9. Lenalidomide for treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Curr Pharm Des; 2012; 18(22):3198-203. PubMed ID: 22571699
[TBL] [Abstract][Full Text] [Related]
10. Effect of lenalidomide therapy on hematopoiesis of patients with myelodysplastic syndrome associated with chromosome 5q deletion.
Ximeri M; Galanopoulos A; Klaus M; Parcharidou A; Giannikou K; Psyllaki M; Symeonidis A; Pappa V; Kartasis Z; Liapi D; Hatzimichael E; Kokoris S; Korkolopoulou P; Sambani C; Pontikoglou C; Papadaki HA;
Haematologica; 2010 Mar; 95(3):406-14. PubMed ID: 19773257
[TBL] [Abstract][Full Text] [Related]
11. [Analysis of clinical characteristics, treatment response rate and survival of 77 myelodysplastic syndrome patients with del (5q) syndrome].
Liu D; Xu ZF; Qin TJ; Li CW; Hu NB; Pan LJ; Qu SQ; Li B; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):895-900. PubMed ID: 31856436
[No Abstract] [Full Text] [Related]
12. Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion.
Chesnais V; Renneville A; Toma A; Lambert J; Passet M; Dumont F; Chevret S; Lejeune J; Raimbault A; Stamatoullas A; Rose C; Beyne-Rauzy O; Delaunay J; Solary E; Fenaux P; Dreyfus F; Preudhomme C; Kosmider O; Fontenay M;
Blood; 2016 Feb; 127(6):749-60. PubMed ID: 26626993
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
15. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
16. A calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromes.
Fang J; Liu X; Bolanos L; Barker B; Rigolino C; Cortelezzi A; Oliva EN; Cuzzola M; Grimes HL; Fontanillo C; Komurov K; MacBeth K; Starczynowski DT
Nat Med; 2016 Jul; 22(7):727-34. PubMed ID: 27294874
[TBL] [Abstract][Full Text] [Related]
17. Deep sequencing of bone marrow microenvironments of patients with del(5q) myelodysplastic syndrome reveals imprints of antigenic selection as well as generation of novel T-cell clusters as a response pattern to lenalidomide.
Mährle T; Akyüz N; Fuchs P; Bonzanni N; Simnica D; Germing U; Asemissen AM; Jann JC; Nolte F; Hofmann WK; Nowak D; Binder M
Haematologica; 2019 Jul; 104(7):1355-1364. PubMed ID: 30655375
[TBL] [Abstract][Full Text] [Related]
18. Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion.
Oliva EN; Cuzzola M; Nobile F; Ronco F; D'Errigo MG; Laganà C; Morabito F; Galimberti S; Cortelezzi A; Aloe Spiriti MA; Specchia G; Poloni A; Breccia M; Ghio R; Finelli C; Iacopino P; Alimena G; Latagliata R
Eur J Haematol; 2010 Sep; 85(3):231-5. PubMed ID: 20491881
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.
Komrokji RS; List AF
Hematol Oncol Clin North Am; 2010 Apr; 24(2):377-88. PubMed ID: 20359632
[TBL] [Abstract][Full Text] [Related]
20. Refractory primary immune thrombocytopenia with subsequent del(5q) MDS: complete remission of both after lenalidomide.
Mortensen TB; Frederiksen H; Marcher CW; Preiss B
BMJ Case Rep; 2017 Jan; 2017():. PubMed ID: 28052942
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
